Financial Counselors Inc. Sells 262 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Financial Counselors Inc. lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 11.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,119 shares of the company’s stock after selling 262 shares during the period. Financial Counselors Inc.’s holdings in IDEXX Laboratories were worth $1,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of IDXX. Norges Bank purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $512,190,000. International Assets Investment Management LLC increased its holdings in IDEXX Laboratories by 51,631.3% during the fourth quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock valued at $304,075,000 after buying an additional 546,775 shares during the period. Capital Research Global Investors purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $135,910,000. TD Asset Management Inc increased its holdings in IDEXX Laboratories by 178.8% during the fourth quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock valued at $144,317,000 after buying an additional 166,751 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $78,001,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IDXX has been the topic of several research reports. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Barclays cut their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Finally, Morgan Stanley cut their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a report on Tuesday, May 14th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $586.63.

View Our Latest Report on IDXX

Insider Transactions at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the sale, the director now directly owns 161 shares in the company, valued at $87,068.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.18% of the company’s stock.

IDEXX Laboratories Trading Down 1.2 %

NASDAQ:IDXX opened at $477.89 on Wednesday. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The firm has a fifty day simple moving average of $499.62 and a 200-day simple moving average of $523.27. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $39.47 billion, a P/E ratio of 46.26, a PEG ratio of 3.95 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The business had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

See Also

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.